Merck and Moderna said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.
The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.
Merck and Moderna expect to start a phase 3 study of the combination next year. That’s generally the last and largest clinical study before a drug is submitted to regulators for approval. The potential vaccine aims to train a patient’s immune system to recognize and respond specifically to mutations in their tumor. Keytruda, Merck’s top seller, primes the body’s immune system to detect and fight tumor cells.
Shares of Moderna jumped more than 8% in premarket trading, while Merck rose more than 2% and futures indexes increased slightly.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial.
Read more »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said.
Read more »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Read more »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Read more »
Experimental mRNA cancer vaccine with immunotherapy reduces risk of melanoma returning, preliminary study finds | CNNAn experimental personalized mRNA vaccine in combination with the immunotherapy Keytruda reduced the risk of recurrence or death from melanoma in patients who had already had surgery, Moderna and Merck said Tuesday.
Read more »
Stocks making the biggest moves in the premarket: Oracle, Boeing, Moderna and moreThe stocks making the biggest moves in premarket trading include Oracle, Boeing, Moderna, and more.
Read more »